Susanne Schnittger

Author PubWeight™ 217.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BRAF mutations in hairy-cell leukemia. N Engl J Med 2011 7.05
2 Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2013 4.50
3 Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008 4.26
4 Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011 3.73
5 Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2012 3.43
6 Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013 3.10
7 Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2009 3.07
8 Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 2002 3.05
9 Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 2011 2.71
10 AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009 2.41
11 Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010 2.29
12 Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006 2.22
13 Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004 2.21
14 Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006 2.20
15 A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007 2.19
16 Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2008 2.01
17 Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009 1.98
18 Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008 1.90
19 Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 2006 1.88
20 SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012 1.85
21 Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005 1.76
22 Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010 1.75
23 Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006 1.74
24 Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood 2007 1.72
25 Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 2005 1.69
26 Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013 1.68
27 The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005 1.68
28 A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012 1.64
29 A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004 1.63
30 Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011 1.56
31 Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 2003 1.55
32 Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005 1.55
33 Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A 2004 1.53
34 Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009 1.51
35 The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004 1.51
36 Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002 1.51
37 Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2008 1.51
38 AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003 1.49
39 Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004 1.49
40 Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003 1.49
41 Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. Leuk Lymphoma 2007 1.46
42 Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma 2012 1.45
43 Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res 2012 1.44
44 Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007 1.41
45 Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 2006 1.40
46 The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer 2013 1.39
47 Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia. Leuk Lymphoma 2006 1.37
48 Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013 1.35
49 Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010 1.33
50 Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008 1.25
51 Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat 2013 1.18
52 Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood 2012 1.18
53 Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 2007 1.17
54 Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012 1.17
55 Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009 1.17
56 Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica 2008 1.17
57 Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica 2009 1.16
58 The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 2010 1.16
59 Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005 1.14
60 NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008 1.14
61 Robustness of amplicon deep sequencing underlines its utility in clinical applications. J Mol Diagn 2013 1.13
62 Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 2005 1.11
63 Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 2010 1.11
64 Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005 1.11
65 Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010 1.11
66 Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014 1.10
67 Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms. Genes Chromosomes Cancer 2011 1.09
68 Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol 2011 1.09
69 Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica 2005 1.09
70 Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood 2011 1.08
71 Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica 2011 1.08
72 KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2004 1.07
73 Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008 1.07
74 Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases. Haematologica 2014 1.06
75 Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002 1.06
76 High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 2012 1.04
77 Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. Haematologica 2011 1.04
78 Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011 1.04
79 Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2009 1.03
80 Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 2005 1.00
81 ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer 2011 1.00
82 Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer 2014 0.99
83 Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms. Br J Haematol 2010 0.98
84 Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2003 0.98
85 Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood 2010 0.98
86 Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 2013 0.98
87 Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol 2005 0.97
88 A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood 2002 0.97
89 Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol 2012 0.97
90 The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010 0.97
91 Correlation of protein expression and gene expression in acute leukemia. Cytometry B Clin Cytom 2003 0.96
92 A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. Blood 2010 0.96
93 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2002 0.94
94 Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. Genes Chromosomes Cancer 2006 0.94
95 Pattern robustness of diagnostic gene expression signatures in leukemia. Genes Chromosomes Cancer 2005 0.94
96 TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol 2011 0.93
97 Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood 2014 0.93
98 Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 2009 0.93
99 Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 2005 0.92
100 Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. Blood 2013 0.91
101 Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases. PLoS One 2013 0.90
102 Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 2009 0.90
103 CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis. Br J Haematol 2013 0.90
104 Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer 2011 0.90
105 Molecular diagnostics in acute leukemias. Clin Chem Lab Med 2009 0.90
106 AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 2005 0.90
107 Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia. Genes Chromosomes Cancer 2010 0.90
108 Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 2003 0.89
109 The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2007 0.89
110 A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica 2008 0.89
111 The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene 2003 0.88
112 Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003 0.88
113 Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 2004 0.88
114 Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer 2012 0.87
115 Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization. Br J Haematol 2013 0.87
116 A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006 0.87
117 Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia. ScientificWorldJournal 2011 0.87
118 Impact of integrating clinical and genetic information. In Silico Biol 2002 0.86
119 Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Leuk Lymphoma 2014 0.86
120 The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica 2005 0.86
121 Distinct sequences on 11q13.5 and 11q23-24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients. Genes Chromosomes Cancer 2004 0.86
122 Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Ann Hematol 2012 0.86
123 Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006 0.86
124 Treatment of older patients with AML. Crit Rev Oncol Hematol 2005 0.86
125 Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol 2013 0.86
126 Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. Cancer Genet Cytogenet 2010 0.85
127 Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. Cancer Genet Cytogenet 2004 0.85
128 Quantification of rare NPM1 mutation subtypes by digital PCR. Br J Haematol 2014 0.84
129 Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 2002 0.84
130 Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. Eur J Haematol 2013 0.84
131 Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Ann Hematol 2012 0.84
132 Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood 2007 0.84
133 Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol 2005 0.84
134 Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 2010 0.83
135 A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. Haematologica 2006 0.83
136 Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn 2011 0.83
137 Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults. Leuk Res 2006 0.83
138 EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia. Br J Haematol 2012 0.83
139 Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia. Hematol J 2002 0.83
140 Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 2006 0.83
141 Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene. Br J Haematol 2014 0.82
142 Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004 0.82
143 CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. Haematologica 2011 0.82
144 Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood 2012 0.82
145 Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica 2012 0.82
146 Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br J Haematol 2013 0.82
147 Chromosomal organization and localization of the human histone deacetylase 9 gene (HDAC9). Biochem Biophys Res Commun 2002 0.81
148 Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005 0.81
149 Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst 2005 0.80
150 Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy. Leuk Res 2005 0.80
151 Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms. Cytometry B Clin Cytom 2013 0.80
152 Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. Cancer 2006 0.80
153 Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014 0.79
154 Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 2011 0.79
155 The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer 2009 0.79
156 Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid. Br J Haematol 2003 0.79
157 Tracing the development of acute myeloid leukemia in CBL syndrome. Blood 2014 0.78
158 Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid. J Gene Med 2003 0.78
159 Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2007 0.78
160 Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010 0.78
161 Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica 2012 0.78
162 Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. Biol Blood Marrow Transplant 2010 0.78
163 Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation. Br J Haematol 2010 0.77
164 Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. Adv Hematol 2011 0.77
165 Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 2002 0.77
166 Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. Cancer Genet Cytogenet 2009 0.77
167 Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. Cancer Genet Cytogenet 2007 0.77
168 Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia. Arch Pathol Lab Med 2005 0.77
169 Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leuk Res 2011 0.77
170 Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. Biol Blood Marrow Transplant 2009 0.77
171 Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients. Cytometry B Clin Cytom 2012 0.76
172 Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. Exp Hematol 2013 0.76
173 Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol 2007 0.76
174 Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. Cancer Genet Cytogenet 2009 0.76
175 Mutation analysis of the Nijmegen breakage syndrome gene (NBS1) in nineteen patients with acute myeloid leukemia with complex karyotypes. Leuk Lymphoma 2003 0.76
176 A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 2007 0.76
177 Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin Hematol 2003 0.76
178 A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet 2007 0.76
179 Monitoring of acute myeloid leukemia by flow cytometry. Curr Oncol Rep 2003 0.76
180 Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia. Br J Haematol 2014 0.75
181 Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. Leuk Res 2012 0.75
182 Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients. Cytometry B Clin Cytom 2015 0.75
183 Gene expression profiling as a diagnostic tool in acute myeloid leukemia. Am J Pharmacogenomics 2004 0.75
184 [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]. Med Klin (Munich) 2007 0.75
185 A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next-generation sequencing can be revealed by comparative bioinformatic analyses. Br J Haematol 2014 0.75
186 Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients. Cytometry B Clin Cytom 2016 0.75
187 A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease. Eur J Haematol 2011 0.75
188 Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. Hematol J 2004 0.75
189 Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement. Cancer Genet Cytogenet 2003 0.75
190 Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. Leuk Lymphoma 2005 0.75
191 Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma 2011 0.75
192 Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). Cancer Genet Cytogenet 2006 0.75
193 [Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]. Med Klin (Munich) 2006 0.75
194 Treatment of AML in biological subgroups. Hematology 2005 0.75
195 Role of gene expression profiling for diagnosing acute leukemias. Rev Clin Exp Hematol 2005 0.75
196 Absence of SCL mutations in myeloid malignancies. Br J Haematol 2003 0.75
197 Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie 2009 0.75